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Abstract 
Background: Automation of cell therapy manufacturing promises higher productivity of cell factories, more eco-
nomical use of highly-trained (and costly) manufacturing staff, facilitation of processes requiring manufacturing 
steps at inconvenient hours, improved consistency of processing steps and other benefits. One of the most broadly 
disseminated engineered cell therapy products is immunomagnetically selected CD34+ hematopoietic “stem” cells 
(HSCs).
Methods: As the clinical GMP-compliant automat CliniMACS Prodigy is being programmed to perform ever more 
complex sequential manufacturing steps, we developed a CD34+ selection module for comparison with the stand-
ard semi-automatic CD34 “normal scale” selection process on CliniMACS Plus, applicable for 600 × 106 target cells out 
of 60 × 109 total cells. Three split-validation processings with healthy donor G-CSF-mobilized apheresis products were 
performed; feasibility, time consumption and product quality were assessed.
Results: All processes proceeded uneventfully. Prodigy runs took about 1 h longer than CliniMACS Plus runs, albeit 
with markedly less hands-on operator time and therefore also suitable for less experienced operators. Recovery of 
target cells was the same for both technologies. Although impurities, specifically T- and B-cells, were 5 ± 1.6-fold 
and 4 ± 0.4-fold higher in the Prodigy products (p = ns and p = 0.013 for T and B cell depletion, respectively), T cell 
contents per kg of a virtual recipient receiving 4 × 106 CD34+ cells/kg was below 10 × 103/kg even in the worst 
Prodigy product and thus more than fivefold below the specification of CD34+ selected mismatched-donor stem cell 
products. The products’ theoretical clinical usability is thus confirmed.
Conclusions: This split validation exercise of a relatively short and simple process exemplifies the potential of auto-
matic cell manufacturing. Automation will further gain in attractiveness when applied to more complex processes, 
requiring frequent interventions or handling at unfavourable working hours, such as re-targeting of T-cells.
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Background
The promise of automation of cell therapy processing is 
several-fold. A closed system might allow the process to 
be performed in a less strictly controlled environment 
than currently (class A in B or 100 in 1000), or for sev-
eral processes to proceed concurrently within the same 
room of a cell factory. Automation is expected to be 
labor saving, and specifically for very complex processes 
it might add stability and convenience, for instance with 
respect to the timing of sequential process steps (espe-
cially at inconvenient hours). With respect to product/
process quality, improved stability/predictability of out-
comes was posited as a likely outcome; experience thus 
far does not unequivocally support this expectation [1–
3]. Before automats will be programmed to perform very 
complex processes consisting of a sequence of orches-
trated process steps, such as washes, stimulations, incu-
bations, selections, etc., the individual building blocks 
must be programmed and put to the test. Moreover, for 
cost effectiveness of the automats, customers may expect 
to perform all standard processes on one device. There-
fore, an immunomagnetic selection module was gener-
ated for the cell processing automat CliniMACS Prodigy 
(referred to as “Prodigy” throughout the remainder of the 
manuscript) to copy the CD34 “normal scale” selection 
module for the established semi-automatic CliniMACS 
Plus System, although performance of CliniMACS Plus 
is excellent, highly robust and not particularly challeng-
ing nor time-consuming for cellular therapy laboratories. 
The specific technical challenge of the overall relatively 
simple CD34 selection process is the near-homogeneous 
enrichment of stem cells with minimal contamination 
by non-target cells that can be achieved with magnet, 
column and reagent, components which are shared by 
both systems. The number of contaminating cells largely 
represents the device’s efficiency at flushing unwanted 
cells from the complex tubing systems and less so, non-
specific immunomagnetic retention. Previous analyses 
comparing outcomes of CD34 selections with the “large-
scale” process on Prodigy versus on CliniMACS Plus 
had suggested greater non-target cell reduction in Clini-
MACS Plus products [4, 5]. In light of these data, the 
manufacturer re-designed the process on Prodigy with 
the aim to further reduce non-target cells. At the same 
time, the process became scalable, as the “normal-scale” 
module was introduced which uses only one vial of Clini-
MACS CD34 reagent. This allows for magnetic labelling 
at reduced material costs for smaller cell products of not 
more than 600 × 106 CD34+ cells and 60 × 109 WBCs. 
The “normal scale” Prodigy process was tested here for 
the first time. By performing split validations, where cells 
from the same G-CSF mobilized apheresis product were 
concurrently manipulated with both devices, product 
variables affecting outcomes were controlled and direct 
comparison of process outcomes was for the first time 
facilitated. The quality of the processes is described by 
feasibility, process time and labor consumption, as well as 
CD34 recovery and the efficiency of immune cell deple-
tion. The manuscript presents several novelties about the 
automatic Prodigy CD34 selection process, albeit each 
one modest, namely, split validation, first reported use 
of the re-designed “LP-34 Enrichment” process and first 
reported use of the “normal scale” module.
Methods
Donors and cells
Peripheral blood apheresis products from G-CSF mobi-
lized healthy volunteer donors were obtained during 
aphereses where favourable donor-recipient weight ratio 
and mobilization efficiency enabled the extraction of a 
large excess of cells within the 300  min apheresis dura-
tion allowed per German guidelines. Two such aphereses 
were performed; the second one served as starting mate-
rial for split runs two and three. Donor assessment was 
done as described [6]. Stem cell donation for these vali-
dations required donors’ written informed consent. The 
protocol was approved by the ethics committee of Goe-
the University Medical School (#468/13) and was per-
formed in agreement with the Helsinki declaration in its 
current version. Aphereses were performed with Terumo 
BCT Spectra Optia devices as described [7, 8]. Collection 
targets were the same as for clinical routine, i.e. hemato-
crit  <4  % and maximal WBC extraction at the possible 
expense of higher neutrophil and platelet contents in 
apheresis products [7, 8]. Three products containing 37, 
46 or 54 ×  109 total WBC and 811, 916 or 1145 ×  106 
total CD34+  cells were obtained. Products contained 
8–16-fold more T-cells and 3–4-fold more B-cells than 
CD34+ target cells. Collections and selections were done 
in Q3 of 2015.
Immunomagnetic selection
The CliniMACS Plus and Prodigy devices [3, 5, 9, 10], 
CliniMACS TS and Prodigy TS310 tubing sets, Clini-
MACS CD34 reagent (1 vial each) and CliniMACS 
PBS/EDTA buffer were obtained from Miltenyi Biotec 
(Bergisch-Gladbach, Germany). NaCl 0.9  %, H2O ad. 
inj. and human serum albumin (HSA) were from Bax-
ter (Unterschleißheim, Germany). Both the CliniMACS 
Plus and Prodigy “normal scale” CD34 selection mod-
ules’ specifications are up to 60  ×  109 total leukocytes 
or 600 × 106 CD34+ cells, and one vial of CD34 reagent 
(the same reagent for both devices) is used to enrich 
the CD34+  cells. CliniMACS Plus selections were per-
formed according to local SOP which are identical with 
manufacturer-recommended protocols; the method was 
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previously published [9]. Briefly, platelets were depleted 
by successive soft-spins, cells were incubated with Clini-
MACS CD34 Reagent (monoclonal CD34 antibody 
coupled to superparamagnetic nanobeads), washed to 
remove free antibody and then connected to a TS tubing 
system which was fitted on the CliniMACS Plus device. 
CliniMACS Plus subsequently automatically performed 
the column application, wash and elution steps. Prodigy 
selections used the same reagent; a TS310 tubing set was 
installed and all liquids were connected as prompted by 
the device. After starting the selection, the process was 
completely automatically guided by a release candidate 
version of the “LP-34 Enrichment” process for Prodigy 
software version 1.2.0, including both “large scale” and 
“normal scale” options. In view of the information gained 
during evaluation of the “large-scale” CD34 selection 
process, [4, 5] in Prodigy software version 1.2.0 “LP-34 
Enrichment” “large scale” and “normal scale” processes 
were modified from the version used in the referenced 
work (1.1.4 or prior) to further reduce non-target cell 
trapping in the tubing system, by increasing the intensity 
of the washing steps of the separation column and pre-
column. The “LP-34 Enrichment” process together with 
Prodigy software version 1.2.0 not yet being CE marked, 
none of the cell products were intended for clinical use.
Assessment of selection outcomes
Leukocyte concentrations in starting population, non-
target and target population were determined using the 
Sysmex XT1800 (Norderstedt, Germany) automatic 
hemocytometer. Flow cytometry was performed with 
FACSCalibur and LSRFortessa (Becton–Dickinson, Hei-
delberg, Germany). Cells were stained with the follow-
ing antibodies (all from BD Biosciences unless otherwise 
noted): anti-CD45-FITC (2D1)/anti-CD34-PE (8G12) 
(BD Stem Cell Reagent), anti-CD14-V450 (MφP9), 
anti-CD3-APC (SK7), anti-CD4-AmCyan (SK3), anti-
CD8-APC-Vio770 (BW135/80, Miltenyi Biotec), anti-
CD20-APC-eFluor780 (2H7, eBioscience, Frankfurt, 
Germany), anti-CD56-PE-Cy7 (CMSSB, eBioscience). 
To assess viability, 7AAD (BD Biosciences) was added 
to the FACS suspension buffer. IVD grade reagents were 
used where possible. Three platforms each were tested 
on apheresis product and positive fraction, i.e. the com-
mercial single-platform SCE-kit (BD), [11] our clinical 
routine single-platform residual T-cell detection panel, 
validated to detect 1 T-cell in 10 × 103 non-T-cells with 
a precision of ±20 % (0.8–1.25 T-cells per 10 × 103 non-
T-cells), and a second residual cell identification panel 
designed for extended characterization of leukocyte 
subsets for the purpose of research/development stud-
ies such as this one, as previously reported [4]. Unless 
otherwise indicated, all cell concentrations, frequencies 
or numbers refer to 7AAD-negative (viable) cells only. 
In two split-validations, colony forming activity was 
assessed on the final products; aliquots of cells were 
plated in commercially available cytokine-replete semi-
solid media (MethoCult H4434, Stem Cell Technologies, 
Vancouver, BC) and read after 2 weeks’ incubation under 
standard conditions, using an inverted microscope with 
2.5× magnification, as described [11].
Goals of the study
The aims of the study were to test feasibility of CD34 cell 
selection with the “normal scale” CD34 selection mod-
ule on Prodigy and to compare type and quantity of con-
taminating non-target cells in Prodigy- and concurrently 
generated CliniMACS Plus-products. The pre-defined 
pass criteria for the validation exercise as outlined in 
the change control process was generation of three suc-
cessive Prodigy products meeting the specification of an 
allogeneic CD34-selected product, for which our insti-
tution holds a marketing authorization. Besides being 
sterile and non-infectious with a panel of blood-trans-
missible agents, products must contain a dose of viable 
CD34+ cells of ≥4 × 106/kg and ≤50 × 103 T-cells/kg of 
the recipient (i.e. T-cell frequency cannot exceed 1.25 % 
of the CD34+  cell frequency). B-cell content must be 
measured and declared. This specification is based on a 
joint position paper by the German societies for Hema-
tology/Oncology DGHO, Pediatric Hematology/Oncol-
ogy GPOH and Transfusion Medicine DGTI and thus 
applies to all licensed allogeneic CD34 selected trans-
plants in Germany.
Statistics
Data were entered into Excel (Microsoft, Redmond, 
WA) spreadsheets from which descriptive statistics were 
extracted. −log T-cell depletion was calculated as the 
negative logarithm to base 10 of number of total T-cells 
in the final product divided by the number of T-cells 
in the apheresis product [12]. Student’s t test was used 
to identify statistically significant differences between 




Three concurrent CliniMACS Plus and Prodigy selec-
tion split-runs were performed; all were successful in 
that they proceeded without issues and generated highly 
pure CD34 products. At the start of the selection pro-
cesses, apheresis products were 20–44 h old. For details 
on selections with CliniMACS Plus, please refer to the 
user handbook [13]. Briefly, platelets are removed by 
soft spins of the apheresis product in centrifuge bags, 
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leukocytes are incubated with CD34 reagent, excess rea-
gent is removed by successive washes, after which the cell 
suspension is applied to the CliniMACS Plus which per-
forms an automatic column selection and elution into the 
target cell bag. Prodigy selections were facilitated by the 
user interface which guides the user through tubing set 
installation and cell and reagent connection. Priming and 
subsequently the selection process are initiated by press-
ing the start button, beyond which the process proceeds 
automatically. Other user interactions are no longer nec-
essary. Including set-up, the Prodigy process takes in 
mean about 5 ½  h (the speed of instrument set-up sig-
nificantly depends on the experience of the operator). In 
this split-validation exercise, the CliniMACS Plus runs 
were performed by three different operators who needed 
in mean 4 ½ h for the entire process including the platelet 
washes, thus besting Prodigy by about 1 h.
Product properties
Three apheresis products containing in 133−200  ml 
37−54 ×  109 leukocytes, 820–1145 ×  106 CD34+  cells 
and 7.3–13  ×  109 T-cells were evenly divided to serve 
as starting materials for simultaneous selection of 
CD34+ cells with the two systems. Properties of Prodigy 
and CliniMACS Plus CD34+ cell products (target popu-
lation) are detailed in Table 1; briefly, recovery of target 
cells was similar with both (58 ± 5 vs. 60 ± 5 %, respec-
tively) and purity exceeded 96  % CD34+  cells among 
total WBCs. In none of the six processes, the T-cell fre-
quency relative to the CD34+ cells exceeded 0.25 %, thus 
easily meeting the pre-defined specification of ≤1.25 % in 
all cases. Outcomes differed, however, in the calculated 
depletion factor for T-cells (5.78 × 10−5± 8.63 × 10−6 vs. 
1.32 × 10−5± 1.95 × 10−6, respectively, p = 0.033; 4.24 
vs. 4.88 log) and for B-cells (3.52 × 10−4± 6.27 × 10−5 vs. 
9.30 × 10−5± 1.51 × 10−5, respectively, p = 0.016; 3.45 
vs. 4.03 log) in favour of CliniMACS Plus. Flow cytomet-
ric analyses of the target populations are shown in Fig. 1, 
illustrating discernibly greater numbers of non-target 
cells in the Prodigy products. Functionality of selected 
CD34+ cells was tested in colony assays from selections 
2 and 3; similarly to unselected products, approximately 
3.5 CD34+ cells gave rise to one CFU-C with no differ-
ence between selection methods.
Discussion
The split-product validation exercise was performed 
under full GMP and using mobilized apheresis mate-
rial of typical size for clinical products and results are 
thus directly transferrable to routine clinical process-
ing. Clearly both methods are capable of generating the 
desired cell product, i.e. highly enriched CD34+  cells 
with fewer than 1.25  % T-cell admixture, which at least 
in Germany is the common specification of the alloge-
neic CD34+  stem cell (Table 2) product for use in mis-
matched (typically haplo-identical) transplantation. In 
two separate previous evaluations performance of Prod-
igy with prior Prodigy software versions (1.1.4 by Spohn 
et  al. and, although not specified in the manuscript, an 
even earlier version by Stroncek et al.) was already com-
pared to historical data, obtained with the CliniMACS 
Plus System [4, 5]. The data generated in this split vali-
dation were therefore used to support the application of 
the manufacturer of the system for approval of the CE 
mark from the national authority for the second, scalable 
version of the “LP-34 Enrichment” process offering both 
“normal scale” and “large scale” options CD34 process on 
Prodigy. The system consists of the reagents which are 
the same as are used for the CD34 process on the Clini-
MACS Plus, the Prodigy consumable (tubing set) and the 
new “LP-34 Enrichment process” on Prodigy software 
version 1.2.0.
The fact that only “super-donors” were eligible for 
cell donations for this study implies comparatively high 
CD34+  cell frequencies and thus relatively favourable 
T-cell to CD34+  cell ratios in the apheresis products. 
Considering how –log T-cell depletion is calculated, the 
observed T-cell reduction with both systems is therefore 
quite satisfactory.
Work by Stroncek et  al. [5] as well as our own previ-
ous work [4] with the “large-scale” CD34+ cell selection 
process had suggested slightly less efficient T-cell reduc-
tion on Prodigy than might have been expected based on 
clinical products processed with CliniMACS Plus, but as 
mentioned above, systematic differences between clinical 
and validation apheresis products did not allow for defin-
itive conclusions. Our split validation now confirms sta-
tistically significantly less efficient immune cell depletion 
with the automatic device, although, as mentioned above, 
products meeting specification are generated by both 
devices. Center specific acceptance criteria for clinical 
stem cell products may be different from those used for 
this study and because of higher desired stem cell doses 
or lower tolerance for T-cells may require T-cell frequen-
cies of less than 0.1  % among CD34+  cells (10  ×  106 
CD34+/kg, 10 × 103 T-cells/kg). 3 of 3 and 2 of 3 runs 
fulfil these more stringent requirements for CliniMACS 
Plus and Prodigy respectively, requiring a T cell deple-
tion of more than 4.2 log with the CD34 and T cell fre-
quencies of the leukapheresis products used in this study. 
Non-selected clinical stem cell products may differ con-
siderably in composition, [9] possibly affecting separation 
performance additionally to impacts by design and tub-
ing set of the system used for processing. In the largest 
published work to this topic, above-mentioned 4.2 logs 
T-cell depletion was achieved in 75 % of 139 CliniMACS 
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Plus CD34 selected grafts [9]. With respect to generating 
CD34-selected stem cell products, larger studies will be 
required to evaluate whether the automat Prodigy results 
in a more consistent T cell depletion of more than 4.2 
log than the currently used semi-automat CliniMACS 
Plus, although available data suggests that with the cur-
rent software and consumable it might not. The lineage 
distribution of non-CD34+  cells in the final product 
(TARGET) differed somewhat from the starting popula-
tion (ORI), in that T-cells were relatively more efficiently 
depleted (frequency among non-CD34+  MNCs three-
fold lower than in TARGET vs. in ORI) than B-cells (two-
fold higher) and monocytes (one-third higher), but with 
no striking differences between the selection methods. 
Thus Prodigy products contained approximately five-
fold, fourfold and sevenfold greater numbers of residual 
T-cells, B-cells and monocytes than CliniMACS Plus 
products, i.e. non-target cell contamination was not spe-
cific or preferential for one lineage. While Prodigy does 
not reduce the total process time over CliniMACS Plus 
Table 1 Product properties
Split run #1 Split run #2 Split run #3
CliniMACS Prodigy CliniMACS Prodigy CliniMACS Prodigy
Apheresis product
 Volume (ml) 70 66 100 100 80 80
 WBC (×106/ml) 269.8 272.6 268.3 268.3 287.4 287.4
 WBC (×109) 18.9 18 26.8 26.8 23 23
 Hkt (%) 2.5 2.5 1.3 1.3 1.7 1.7
 Plt (×106/ml) 2740 2740 1934 1934 1971 1971
 Plt total (×109) 191.8 180.8 193.4 193.4 157.7 157.7
 T-cells (×106) 6818 6428 4587 4587 3670 3670
 CD4+ (% of CD3 +) 70 70 58 58 58 58
 CD8+ (% of CD3 +) 30 30 42 42 42 42
 CD34+ cells (%) 2.2 2.2 2.1 2.1 2.1 2.1
 CD34+ cells (×106) 417.8 393.3 572.6 572.6 458.1 458.1
 B-cells (×106) 1813 1709 1550 1550 1240 1240
Non-target fraction
 Volume (ml) 298 393 328 389 301 394
 WBC (×109) 16.1 14.6 23.8 22.3 14.5 16.8
 CD34+ cells (%) 0.2 0.2 0.2 0.2 0.3 0.2
 CD34+ cells (×106) 33 31 49 44 47 37
Target fraction
 Volume (ml) 40 78 41 82 39 76
 WBC (×109) 0.27 0.2 0.39 0.39 0.24 0.29
 Plt (x106/ml) 4 4 7 8 5 7
 T-cells (×106) 0.08 0.47 0.05 0.2 0.06 0.21
 CD4+ (% of CD3 +) 50 50 9 43 11 24
 CD8+ (% of CD3 +) 50 50 91 57 89 76
 CD34+ cells (%) 97 96.1 99 98.2 98.8 98
 CD34+ cells (×106) 265.7 191 387.9 379.9 234 273.4
 B-cells (×106) 0.2 0.47 0.16 0.74 0.08 0.38
 NK-cells (K/µl) n.d. n.d. n.d. n.d. n.d. n.d.
 Monocytes (K/µl) 0.004 0.022 0.012 0.038 0.009 0.029
 Ratio T:CD34+ 3.01−4 2.45−3 1.27−4 5.18−4 2.67−4 7.73−4
 T-cells/4 × 106 CD34+ 1204.5 9803.1 507.4 2072 1066.5 3090.6
 B-cells/4 × 106 CD34+ 3011.1 9803.1 1691.4 7770.1 1333.1 5558.6
 Recovery CD34+ (%) 63.6 48.6 67.7 66.3 51.1 59.7
 B-cell depletion 1.10−4 2.74−4 1.06−4 4.76−4 6.29−5 3.07−4
 T-cell depletion 1.17−5 7.28−5 1.07−5 4.29−5 1.70−5 5.76−5
Page 6 of 7Hümmer et al. J Transl Med  (2016) 14:76 
(on the contrary), the hands-on operator time is reduced 
by almost 2 h. Moreover, the Prodigy process could run 
unsupervised or supervised remotely over-night so that 
cells could be generated during unfavourable working 
hours. Thus selections could be routinely started on the 
apheresis day as opposed to the day thereafter, yield-
ing a several hours fresher product. The earlier release 
of these products would then allow for transportation 
to transplant centers for same-day infusion. Avoidance 
of unfavourable working hours will become a more rel-
evant issue with complex cell manipulation processes, 
as is already apparent with the automated process for 
enrichment of virus specific T cells [1] which no longer 
requires manual addition of peptide reagent between 
midnight and 2 am and will be even more accentuated as 
longer multi-step processes are developed on the auto-
mat. Automation of CD34+ cell selection also optimizes 
personnel and clean-room utilization, with the automat 
taking over the “second (unsupervised) shift” and by con-
currently operating several automats within the same 
clean room. While few centers will generate sufficient 
CD34+ cell products to render this issue relevant for the 
process tested here, the same advantages will similarly 
apply to other, frequently requested cell products as may 
be established with the advent of T-cell products re-tar-
geted against cancer antigens, as well as the availability 
of automatic systems may encourage centralization of cell 
selection processes.






















CD34  FSC  CD34  FSC  
Fig. 1 Flow cytometric appearance of CliniMACS Plus or Prodigy generated CD34 selection products: excerpts from the flow cytometric analysis 
(quality control) of the final products from all three runs are depicted; in all cases 100,000 CD45 + events (WBC) were acquired. For Prodigy and 
CliniMACS Plus, respectively, the left panels show SSC over CD34; besides CD34+ target cells (orange), SSC-intermediate, CD34-negative monocytes 
(blue) and within the lymphocyte region (SSC-low, CD34-negative), T-cells (red) are visible. The right panels depict CD45+ CD3+ events for Prodigy 
and CliniMACS Plus, respectively. The greater content of monocytes and T-cells in Prodigy products is readily visible. Corresponding numbers are 
given in Table 1
Table 2 Comparative product quality (target fraction; 
mean ± SEM)
CliniMACS Prodigy t test
T-cells/4 × 106 CD34+ 926 ± 213 4989 ± 2425 0.171
B-cells/4 × 106 CD34+ 2012 ± 1512 7711 ± 6664 0.013
Recovery CD34+ 61 ± 5 58 ± 5 0.736
B-cell depletion 9.30−5 ± 1.51−5 3.52−4 ± 6.27−5 0.016
T-cell depletion 1.32−5 ± 1.95−6 5.78−5 ± 8.63−6 0.007
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Downsides, clearly, are the apparent superiority of 
the semi-manual process with respect to non-target cell 
contamination and the difficulties rescuing a partly pro-
cessed product in case of a system failure.
Conclusions
This is the first report on performing the “normal scale” 
CD34 selection with the “LP-34 Enrichment” process on 
the Prodigy. The Prodigy is unconditionally suitable to 
perform the CD34 selection process, in that all valida-
tion products met the pre-defined specification of the 
cell product “G-CSF mobilized allogeneic HPCs, CD34 
selected”, a marketing authorization for which has been 
issued to several cell therapy laboratories in Germany, 
including the one the authors are affiliated with. Recov-
ery of target cells was equal to that reported for the semi-
automatic method. Final product content of potentially 
allo-reactive T-cells, as well as B-cells and monocytes was 
statistically significantly higher. Prodigy reduces opera-
tor time by approximately half and at least theoretically 
allows unsupervised, e.g. nocturnal, operation (although 
may be limited by liability issues). Although an automat 
like Prodigy is simple enough for any transplant unit to 
use (and a clean room facility may be dispensable for its 
operation), the quality control (residual T-cell quantifi-
cation) is quite demanding and should be performed in 
centers of excellence. World-wide shipping from a very 
small number of centralized manufacturing sites is con-
ceivable but may not be cost-effective.
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